(10.2%) died. Such individuals were censored at the date of moving or of death. The median follow-up period for all participants was 12.0 years. Cause-specific mortality was also determined individually in terms of total stroke (ICD-9 codes 430-438; ICD-10 codes I60-I69), hemorrhagic stroke (codes 431-432; I60-I61, I69.0, I69.1), ischemic stroke (codes 433-434, 437.7A, 437.7B; I63, I69.3), coronary heart disease (codes 410-414; I20-I25), and total CVD (codes 393-459; I00-I99).
Measurement of Risk Factors
At baseline survey, body mass index (BMI) was calculated as weight (kg) divided by square of height (m 2 ). Height in stocking feet and weight in light clothing were measured. The proportion of obesity (BMI ≥30 kg/m 2 ) was only 1.7% in men and 3.4% in women. Serum triglyceride (TG) and serum total cholesterol (TC) levels were measured with enzyme methods using an RX-30 device (JEOL Ltd, Tokyo, Japan). High-density lipoprotein-cholesterol (HDL-C) was measured with a phosphotungstic acid magnesium method using an MTP-32 device (Corona Electric, Ibaraki, Japan). The measurement of these lipids in the laboratory of the Ibaraki Health Service Association was standardized by the laboratory of the Osaka Medical Center for Health Science and Promotion under the laboratory network program of the US Centers for Disease Control and Prevention (Atlanta, GA, USA). 12 Blood pressure (BP) was measured by trained observers using a standard mercury sphygmomanometer on the right arm of seated participants after a 5-min rest. Plasma glucose levels were measured with a glucose oxidase electrode method using a GA1140 device (ARKRAY, Inc, Kyoto, Japan). Fasting was not required. The time since the last meal was <2 h (25%), 2 h (25%), 3-7 h (33%) and ≥8 h (17%).
An interview was conducted to ascertain smoking status, number of cigarettes smoked per day, usual weekly intake of alcohol in "go" units (a Japanese traditional unit of volume corresponding to 23 g ethanol), which was converted to grams of ethanol per day, and histories of stroke and heart disease. Histories of CVD were also determined by interview in which the subjects were asked if they had been diagnosed as stroke and/or heart disease. Symptoms typical of stroke and coronary heart disease or findings on brain imaging studies and/or ECG were not taken into account.
Definitions of MetS
The components of MetS were defined as: (1) Because waist circumference was not measured in our study, BMI ≥25 kg/m 2 was used as the criterion for being overweight for the analyses; this BMI level is reported to correspond well to the Asian criterion for high waist circumference ≥90 cm in men and ≥80 cm in women. 13 Non-fasting plasma glucose was also used as a criterion for glucose intolerance, because the fasting plasma glucose level was not measured in four-fifths of the participants. We defined elevated glucose as glucose ≥5.55 mmol/L (100 mg/dl) in fasting blood samples and ≥7.22 mmol/L (130 mg/dl) in non-fasting ones.
As shown in Table 1 , MetS was defined as the presence of 3 or more of the components (overweight, elevated TGs, reduced HDL-C, elevated BP and elevated glucose) according to the modified criteria of AHA/NHLBI, and the presence of 2 or more of the same cardiovascular risk factors (elevated TGs, reduced HDL-C, elevated BP and elevated glucose) among overweight persons according to the modified criteria of the IDF. The AHA/NHLBI definition included non-overweight people with 3 or 4 abnormalities of TGs, HDL-C, BP and glucose, who would not be classified as MetS by the IDF criteria.
Statistical Analysis
Sex-specific hazard ratios (HRs) of CVD mortality and the corresponding 95% confidence intervals (95%CI) were calculated with reference to the risk for individuals without each of MetS components or with none of the components, or without MetS, using the Cox proportional hazards model. Elevated TC was defined as ≥5.69 mmol/L (220 mg/dl). We adjusted for age at baseline (years), and for other potential confounding factors including cigarette smoking (neversmokers, ex-smokers, current smokers of 1-19, 20-29 and ≥30 cigarettes/day), usual alcohol intake (never, former, current <23 g/day, 23-45, 46-68 and ≥69 g/day ethanol), time since last meal (<2, 2, 3-7 and ≥8 h) and sex-specific quartiles of serum TC levels.
Participants were stratified into categories according to the number of metabolic risk factors (BMI < or ≥25 kg/m 2 plus 0, 1, 2, 3 or more (≥3), or 2 or more (≥2) of additional risk factors except being overweight). The HRs and corresponding 95%CI of death were calculated with reference to persons with 0 of 4 MetS components. We conducted tests for trend across the categories of the number of metabolic risk factors by assigning median values for each category (0, 1, 2 and ≥3) and testing the significance of this variable. The HRs of mortality for MetS according to the IDF and AHA/NHLBI definitions were also calculated with reference to individuals without MetS. P values for statistical tests were 2-tailed and P<0.05 was regarded as statistically significant. The SAS statistical package (version 9.1; SAS Institute Inc, Cary, NC, USA) was used for the analyses. We also calculated population attributable fractions (PAF) to examine the contribution of the MetS and its components to the risk of CVD mortality, using multivariate HRs of statistical significance and the proportion of cases in each category.
PAF was estimated as [p(HR-1)]/[1+ p(HR-1)],
where p is the proportion of cases falling into the category and HR is the HR in the category. 14 
Results
During the 12-year follow-up, there were 9,282 deaths (5,124 for men; 4,158 for women), comprising 1,317 deaths from total stroke, 569 from hemorrhagic stroke, 716 from ischemic stroke, 704 from coronary heart disease, and 2,674 from total CVD. Table 2 presents the sex-specific HRs (95%CI) for mortality from hemorrhagic stroke, ischemic stroke and coronary heart disease according to metabolic risk factors. Ageadjusted HR for mortality from hemorrhagic stroke was 1.9 in both sexes in the presence of elevated BP. Age-adjusted HRs for mortality from ischemic stroke ranged from 1.3 to 1.5 in the presence of elevated BP and reduced HDL-C in men, and were between 1.5 and 1.7 in the presence of elevated BP and glucose levels in women. Age-adjusted HRs of mortality from coronary heart disease ranged from 1.4 to 1.6 in the presence of elevated BP, elevated glucose and reduced HDL-C in men, and were between 1.4 and 1.9 in the presence of elevated BP and glucose levels in women. Age-adjusted HRs for mortality from total CVD ranged from 1.2 to 1.6 in the presence of elevated BP, elevated glucose and reduced HDL-C in men, and were between 1.4 and 1.7 in the presence of elevated BP and glucose levels in women. Elevated TC was associated with increased mortality from coronary heart disease in men, but not in women. Smoking was associated with increased mortality from hemorrhagic stroke in women, and coronary heart disease and total CVD in both sexes. These associations remained statistically significant after adjustment for confounding factors. Associations between being overweight and diseases outcomes were generally weak and only significant for coronary heart disease in men.
The PAFs of these 4 outcomes were approximately 20-40% for elevated BP in both sexes, whereas the PAFs of coronary heart disease and total CVD were approximately 10-20% for elevated glucose in both sexes, and approximately 20-25% for smoking in men. Table 3 presents the multivariate HRs for mortality from ischemic stroke, coronary heart disease and total CVD according to the number of metabolic risk factors stratified by BMI. In both men and women, a dose-response relationship was found between the number of metabolic risk factors and the HR of mortality from each endpoint for both non-overweight and overweight subgroups. The multivariate HR (95%CI) of total CVD was 1.75 (1.38-2.24) in non-overweight persons with ≥2 risk factors (components of MetS except for overweight) and 1.83 (1.41-2.38) in overweight persons with ≥2 risk factors in men. The respective HRs were 1.97 (1.52-2.55) and 1.90 (1.45-2.49) in women. The HRs of mortality from total CVD for overweight individuals with ≥2 risk factors were similar to those for non-overweight persons with ≥2 other MetS components in both men and women. The PAF in the former category was 10%, and 15% in the latter among both men and women. Furthermore, we also calculated age-specific HR, hazard ratio; CI, confidence interval; PAF, population attributable fraction; TC, total cholesterol. Other abbreviations see in Table 1 .
HRs of mortality from total CVD according to the number of metabolic risk factors stratified by BMI (<25, ≥25 kg/m 2 ), and found similar associations in both age subgroups. For example, the PAF of total CVD among men was 17% for overweight individuals with ≥2 risk factors and 17% for non-overweight ones with ≥2 other MetS components in the age subgroups of 40-64 years, and 6% and 16%, respectively, for the older subgroups of 65-79 years. The respective PAFs among women were 10%, 23%, 12% and 16% (not shown in Table 3 ). Non-overweight individuals with ≥3 risk factors also had a considerable contribution to CVD mortality, even though they were not classified as MetS by the IDF definition. PAF in this category was 6% in men and 5% in women for total CVD mortality. Similar associations were observed for ischemic stroke and coronary heart disease.
Figure shows sex-specific multivariate HRs of mortality from total CVD according to the number of metabolic risk factors stratified by BMI. Although the HR for non-overweight individuals with ≥2 MetS components other than being overweight was similar to that for overweight persons with ≥2 risk factors; the proportion of subjects in the former category was approximately 1.5-2-fold higher than that in the latter. Thus, the number of total CVD deaths for nonoverweight individuals with ≥2 MetS components exceeded substantially that for overweight persons with ≥2 risk factors. Tables 1,2 .
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Similar results were observed for mortality from other endpoints. Table 4 presents the prevalence of MetS and HRs of CVD mortality for MetS according to the 2 definitions. The prevalence of MetS was 26% according to the AHA/NHLBI criteria and 19% according to the IDF definition in either men or women. Multivariate HRs (95%CI) of mortality from coronary heart disease and total CVD for MetS based on the AHA/NHLBI with reference to individuals without MetS were 1.62 (1.31-2.00) and 1.23 (1.09-1.39), respectively, in men, and 1.32 (1.05-1.65) and 1.12 (1.00-1.25), respectively, in women. The respective HRs for MetS by the IDF definition did not reach statistical significance, except for coronary heart disease in men. The PAF for MetS based on the AHA/NHLBI criteria was 15% for coronary heart disease and 6% for total CVD in men and 8% for coronary heart disease in women. The PAF for MetS based on the IDF criteria was 9% for coronary heart disease in men.
Discussion
In this large prospective study of the Japanese general population, we showed that contribution of overweight per se to CVD mortality is not obvious compared with elevated glucose and BP. The excess risk of mortality from total CVD and other endpoints was similar for overweight and non-overweight persons with ≥2 metabolic components in both men and women. Because of the 2-fold higher proportion of non-overweight high-risk individuals, the excess proportion of death was obviously larger for non-overweight persons with ≥2 metabolic components than for persons with Mets by the IDF definition.
It is controversial whether central obesity defined by waist circumference or BMI is essential in the diagnosis The magnitude of the HRs of MetS for total CVD mortality was somewhat smaller in our study than previously reported. 2, 3, [17] [18] [19] Two large meta-analyses in Western countries indicated that the pooled HRs of total CVD deaths for MetS ranged from 1.7 to 1.9. 2, 3 The lower prevalence of obese individuals, lower mortality from ischemic heart disease and higher mortality from hemorrhagic stroke in the Japanese population compared with Western populations may explain the smaller contribution of MetS to CVD, even for middle-aged men, in the present study.
Among the cardiovascular risk factors, elevated BP had the largest impact on mortality from CVD. The PAF of elevated BP ranged from 20% to 40%, which was far larger than that of other metabolic risk factors. Our study also confirmed that the impact of each metabolic risk factor varied among the cardiovascular outcomes. Although elevated BP was strongly associated with mortality from hemorrhagic stroke, 20,21 elevated glucose level was associated with mortality from coronary heart disease 22, 23 in both sexes. In men, reduced HDL 24, 25 and being overweight 26 were also associated with mortality from coronary heart disease.
In our study, serum TC tended to be inversely associated with mortality from hemorrhagic stroke, whereas elevated TC was associated with mortality from coronary heart disease, which was consistent with results from recent studies in the Asia-Pacific region. 27, 28 Being overweight was associated with mortality from coronary heart disease, but not from hemorrhagic or ischemic stroke, which was also consistent with previous Japanese studies. [29] [30] [31] [32] [33] The strengths of our study include the long term followup, sufficient number of deaths, complete follow-up of subjects using basic resident registers and systematic review of death certificates, and gender-specific analysis. To our knowledge, this study is the first large-scale prospective study of the Japanese general population to evaluate the gender-specific impact of each metabolic risk factor to mortality from CVD, stratified by BMI.
Study Limitations
First, the subjects of this study were participants in health checkups for residents with a response rate of 36.4%. Further, male participants were resident non-employees, so it is uncertain whether the findings in men can be generalized. However, the potential selection bias may be small because the rate of all-cause mortality was similar for the study subjects and the total Japanese population. The standard mortality ratio of all-cause mortality for the study participants was 95 (95%CI: 86, 103) for men and 100 (95%CI: 89, 110) for women compared with the total Japanese population in 2000. 34, 35 Second, we used death certificate diagnoses rather than medical records or autopsy findings. Validation studies have been performed to evaluate the accuracy of death certificate diagnosis between the mid-1980 s and the 1990 s in Japan. [36] [37] [38] [39] [40] [41] The positive predictive value and sensitivity for stroke diagnosis were 95% and 87%, respectively. 36 Moreover, previous studies have shown that the diagnosis on death certificates with regard to total stroke and its subtypes is valid because of the widespread use of CT scanning and MRI in Japanese hospitals. 42, 43 As for coronary heart disease, the positive predictive value was lower than that for stroke, ranging from 50% to 78%, but the sensitivity was similar to that for stroke, ranging from 72% to 91%. [36] [37] [38] [39] [40] [41] Third, we used BMI to define central obesity because waist circumference was not measured at the baseline examination. BMI has been used to diagnose overweight in many epidemiological studies and is considered to closely correlate with waist circumference. 13 Fourth, non-fasting blood samples were used for four-fifths of the participants at the baseline examination, which may cause misclassification of participants with elevated plasma glucose or elevated TGs.
In conclusion, non-overweight subjects with metabolic risk factors are at high risk of CVD mortality, as well as overweight subjects with such factors, and the excess mortality was 1.5-fold larger in the former than in the latter. The prevention and control of metabolic risk factors other than being overweight may therefore be important to reduce the burden of CVD in the general population.
